New role of EPAC1 in Anthracycline-induced cardiotoxicity and anticancer therapy

2 September 2019 (10:05 - 10:55)

Organised by:

Abstract

Sign in to view the resources

About the speaker

Miss Anissa BELHADEF

University of Paris-Sud 11 UMR-S 1180, Chatenay-Malabry (France)

6 More presentations in this session

Presentation thumbnail

Effect of calcitriol attenuates doxorubicin-induced cardiac dysfunction in mice model: focus on endothelial-to-mesenchymal transition

Doctor T. Tsai (Kaohsiung, TW)

Presentation thumbnail

Usefulness of cardiac magnetic resonance imaging for early detection of subclinical chemotherapy-related cardiac dysfunction in cancer patients

Doctor Y. Terui (Sendai, JP)

Abstract Slides

Presentation thumbnail

CMR Fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography

Doctor M. Montenbruck (Hamburg, DE)

Presentation thumbnail

Malignancy after Heart Transplantation: Difference in incidence and prognosis between genders. Data from the Spanish post-Heart Transplant Tumor Registry.

Doctor C. Minguito Carazo (A Coruna, ES)

Abstract Slides

Presentation thumbnail

Prevention of heart failure in treatments with trastuzumab and anthracyclines: a meta-analysis

Professor F. Braunschweig (Stockholm, SE)

Abstract Slides

Access the full session

Session thumbnail

Cardio-Oncology: insights from basic , clinical, data science

The Event

ESC Congress 2019

2 September 2019 10:05 CET

You may be interested in

Congress Session

Chronic kidney disease and heart failure

Congress Session

Rare causes of heart failure

Congress Session

Heart failure in the era of precision medicine: insights into pathophysiology and emerging treatments

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources